Senior AstraZeneca exec detained in China amid wider investigation
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his detainment, Leon Wang, executive vice president of international and president...
View ArticlePfizer to invest $1B in China over next five years — reports
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a new phase of growth. Pfizer China President Jean-Christophe Pointeau said ...
View ArticleNkarta drops another cancer program as it leans into autoimmune disease
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects in autoimmune disease. The biotech will stop investigating NKX019 in...
View ArticleLegend names a president of Carvykti; Novo Nordisk's top North America exec...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the commercial future of the biotech's sole marketed cell therapy, among other...
View ArticleBenevolentAI co-founder returns with plan to save drug developer
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It soared to a $2 billion valuation, pitching a...
View ArticleDaiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode deal
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the...
View ArticleEisai slashes Leqembi sales forecast by almost $100M
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most closely-watched drugs. The company now expects that the Alzheimer's treatment will bring...
View ArticleAmgen and AstraZeneca share positive results in chronic rhinosinusitis
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition....
View ArticleFDA action puts Chinese API manufacturer on import block list
The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer Shandong Boyuan Pharmaceutical Co., whose exports to the US have been blocked...
View ArticleHow Trump, RFK Jr. could influence biopharma; Viking presents weight loss...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleFDA approves Autolus’ CAR-T cell therapy for aggressive blood cancer
US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B-cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment....
View ArticleAurion, Alcon enter legal battle over IPO plan
The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech prepares to go...
View ArticleALK-Abelló licenses ARS’ anaphylaxis nasal spray in certain markets for $145M
A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400...
View ArticleCigna says it will not pursue a merger with Humana
Cigna said it will not pursue a merger with rival Humana after reports last month of renewed talks about a potential deal. Talks of a deal
View ArticleAbbVie's schizophrenia drug from Cerevel fails two Phase 2 trials
The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb and...
View ArticleAssertio considers legal options against activist investor accusing company...
Assertio Holdings responded to activist investor Alexander Parker after Parker's firm accused Assertio of fraud. The Buxton Helmsley Group on Friday released an open letter to Assertio’s stockholders,...
View ArticleYorvipath’s approval showcases biopharma’s interest in rare endocrine disorder
Michele Rayes used to take 64 pills a day to manage her hypoparathyroidism, a rare endocrine disorder that impairs calcium levels, dampens daily quality of life and can sometimes lead to chronic kidney...
View Article